MODERN MARKERS OF INFLAMMATION

DOI: https://doi.org/10.29296/25877305-2022-11-08
Issue: 
11
Year: 
2022

A. Morozov, Candidate of Medical Sciences; S. Zhukov, MD; A. Morozova;
S. Zinkovskaya; A. Romanova; V. Ilkaeva; M. Belyak
Tver State Medical University

The analysis of data from modern Russian and foreign literary sources, containing information on the prospects of using markers of inflammation in clinical practice was carried out. Biomarkers of inflammation play an important role in the early and differential diagnosis of certain diseases and pathological processes. In some cases, they are specific and highly informative, and also allow you to track the effectiveness of the therapy. Most reviews note the diagnostic and prognostic value of certain markers. Thus, it can be concluded that the determination of indicators of inflammation markers is a promising method that can serve as a basis for diagnosis, the construction of an individual therapeutic plan, dynamic monitoring of the course and prediction of the disease.
Keywords: 
inflammation
markers of inflammation
C-reactive protein
neopterin
periostin

References: 
  1. Morozov A.M., Sergeev A.N., Armasov A.R. et al. Temperature circulation index as an indicator of the state of the woundary process. Modern problems of science and education. 2021; 1: 41 (in Russ.). DOI: 10.17513/spno.30496
  2. Morozov А.М., Armasov А.R., Sergeev А.N. et al. Influence of pH on the dynamics of the wound process in the postoperative period. Bulletin of the Medical Institute "REAVIZ" (rehabilitation, doctor and health). 2021; 2: 87–91 (in Russ.). DOI: 10.20340/vmi-rvz.2021.2.CLIN.9
  3. Shishkin N.V., Zhukov S.V., Morozov A.M. et al. About inflammation markers, actual in the conditions of a surgical hospital. Moscow Surgical Journal. 2020; 1: 70–7 (in Russ.). DOI: 10.17238/issn2072-3180.2020.1.70-77
  4. Kozlov V.A., Tikhonova E.P., Savchenko A.A. et al. Klinicheskaya immunologiya. Prakticheskoe posobie dlya infektsionistov. Krasnoyarsk: Polikor, 2021; 563 c. (in Russ.). DOI: 10.17513/np.518
  5. Titova O., Kuzubova N., Lebedeva E. Biomarkers for predicting severity and outcome of community-acquired pneumonia. Meditsinskii al'yans. 2018; 2: 55–60 (in Russ.).
  6. Ershov A.V. С-reactive protein in the diagnostics of communicative pneumonia. Consilium Medicum. 2019; 21 (3): 15–9 (in Russ.). DOI: 10.26442/20751753.2019.3.190259
  7. Li H., Sun K., Zhao R. et al. Inflammatory biomarkers of coronary heart disease. Front Biosci (Landmark Ed). 2017; 22 (3): 504–15. DOI: 10.2741/4498
  8. Kattakhodzhaeva M.Kh., Gaibullaeva D.F. Indicators of endothelial dysfunction and markers of systemic inflammation in pregnant women with preeclampsia. Re-health journal. 2020; 2-2 (6): 10–3 (in Russ.). DOI: 10.24411/2181-0443/2020-10041
  9. Rajab I.M., Hart P.C., Potempa L.A. How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression. Front Immunol. 2020; 11: 2126. DOI: 10.3389/fimmu.2020.02126
  10. Gieseg S.P., Baxter-Parker G., Lindsay A. Neopterin, Inflammation, and Oxidative Stress: What Could We Be Missing? Antioxidants (Basel). 2018; 7 (7): 80. DOI: 10.3390/antiox7070080
  11. Gladkikh R.A., Molochniy V.P., Polesko I.V. Neopterin as а Modern Marker of Inflammation. Children Infections. 2016; 15 (2): 19–23 (in Russ.). DOI: 10.22627/2072-8107-2016-15-2-19-23
  12. Ben M.M., Yanchevskaya E.Yu., Mesnyankina O.A. Clinical and diagnostic value of determination of neopterin in atopic dermatitis in children. Kubanskij Nauchnyj Medicinskij Vestnik. 2018; 25 (3): 24–7 (in Russ.). DOI: 10.25207/1608-6228-2018-25-3-24-27
  13. Svistushkin V.M., Chichkova N.V., Pshonkina D.M. Periostin new biological marker of eosinophilic inflammation in patients with chronic rhinosinusitis with nasal polyps and bronchial asthma. Tavricheskii mediko-biologicheskii vestnik. 2017; 20 (3-3): 232–9 (in Russ.).
  14. Shakhova N.V. Periostin as a Biomarker of Bronchial Asthma. Current Pediatrics. 2019; 18 (5): 339–45 (in Russ.). DOI: 10.15690/vsp.v18i5.2056
  15. Patelis A., Alving K., Middelveld R. et al. IgE sensitization to food allergen and airborn allergens in relation to biomarkers of type 2 inflammation in asthma. Clin Exp Allergy. 2018; 48 (9): 1147–54. DOI: 10.1111/cea.13165
  16. James A., Janson C., Malinovschi A. et al. Serum periostin relates to type-2 inflammation and lung function in asthma: data from the large population-based cohort Swedish GA(2)LEN. Allergy. 2017; 72 (11): 1753–60. DOI: 10.1111/all.13181
  17. Petrova O.V., Tarasov D.G., Nikulina D.M. et al. Value of the procalcitonin in cardiosurgery practice. Clin Experiment Surg Petrovsky J. 2018; 1 (19): 51–61 (in Russ.).
  18. Mikhelson E.P., Shlyapnikov S.A., Naser N.R. et al. The diagnostic value of determining the level of procalcitonin in abdominal surgery. Zhurnal MediAl'. 2019; 1 (23): 25–7 (in Russ.). DOI: 10.21145/2225-0026-2019-1-25-27
  19. de Jong E., van Oers J.A., Beishuizen A. et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, openlabel trial. Lancet Infect Dis. 2016; 16 (7): 819–27. DOI: 10.1016/S1473-3099(16)00053-0
  20. Schuetz P., Birkhahn R., Sherwin R. et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin Monitoring SEpsis (MOSES) study. Crit Care Med. 2017; 45 (5): 781–9. DOI: 10.1097/CCM.0000000000002321
  21. Westwood M.E., Ramaekers B.L.T., Whiting P. et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015; 19 (96): V–XXV. DOI: 10.3310/hta19960
  22. Huang D.T., Yealy D.M., Filbin M.R. et al . Procalcitonin - guideduse of antibiotics for lower respiratory tract infection. N Engl J Med. 2018; 379: 236–49. DOI: 10.1056/NEJMoa1802670
  23. Velissaris D., Zareifopoulos N., Karamouzos V. et al. Presepsin as a Diagnostic and Prognostic Biomarker in Sepsis. Cureus. 2021; 13 (5): e15019. DOI: 10.7759/cureus.15019
  24. Rogić D., Juroš GF, Petrik J. et al. Advances and Pitfalls in Using Laboratory Biomarkers for the Diagnosis and Management of Sepsis. EJIFCC. 2017; 28 (2): 114–21.
  25. Abudeyev S.A., Kiselyov K.V., Parinov O.V. et al. Cerebrospinal Fluid Presepsin as a Marker of Nosocomial Infections of Central Nervous System. Russian Sklifosovsky Journal "Emergency Medical Care". 2019; 8 (1): 18–29 (in Russ.). DOI: 10.23934/2223-9022-2019-8-1-18-29
  26. Zhuravleva L.N. Novikova V.I. The significance of the blood serum biomarker presepsin in pneumonia in premature newborns. Vestnik VGMU. 2020; 19 (4): 46–52 (in Russ.). DOI: 10.22263/2312-4156.2020.4A6
  27. Vasilev A.Yu., Kalmykova A.S., Obedin A.N. Importance of inflammation markers for early diagnostics of neonatal sepsis in premature newborns. Vestnik molodogo uchenogo. 2021; 10 (2): 94–8 (in Russ.).
  28. Pugni L., Pietrasanta C., Milani S. et al. Presepsin (Soluble CD14 Subtype): Reference Ranges of a New Sepsis Marker in Term and Preterm Neonates. PLoS One. 2015; 10 (12): e0146020. DOI: 10.1371/journal.pone.0146020
  29. Topcuoglu S., Arslanbuga C., Gursoy T. et al. Role of presepsin in the diagnosis of late-onset neonatal sepsis in preterm infants. J Matern Fetal Neonatal Med. 2016; 29 (11): 1834–9. DOI: 10.3109/14767058.2015.1064885
  30. Çakar E., Çakar Ş.E., Taşan H.A. et al. Diagnostic and Prognostic Value of Presepsin for Subclinical Chorioamnionitis in Pregnancies between 23–28 Week with Preterm Premature Rupture of the Membranes. Balkan Med J. 2016; 33 (6): 668–74. DOI: 10.5152/balkanmedj.2016.160293
  31. Prilutskaya I.A., Kryuk Yu.Y. Levels of tumor necrosis factor alpha in patients with ischemic stroke. Medical Immunology (Russia). 2019; 21 (4): 755–64 (in Russ.). DOI: 10.15789/1563-0625-2019-4-755-764
  32. Ashcheulova T.V., Kovalyova O.N., Gerasimchuk N.N. et al. Endothelial function and activity of proinflammatory cytokines in patients with hypertension associated with obesity. Aktual'nye problemy meditsiny. 2016; 12 (233): 5–14 (in Russ.).
  33. Osipenko M.F., Livzan M.A., Skalinskaya M.I. et al. Fecal calprotectin concentration in the differential diagnosis of bowel diseases. Ter Arkh. 2015; 87 (2): 30–3 (in Russ.). DOI: 10.17116/terarkh201587230-33
  34. Avdeeva A.S. Clinical significance of calprotectin in rheumatic diseases. Rheumatology Science and Practice. 2018; 56 (4): 494–9 (in Russ.). DOI: 10.14412/1995-4484-2018-494-499
  35. Soliman A., Elnadya B., Shakerc R. et al. Potential role of calprotectin as a monitoring biomarker for clinical and sonograph-ic activity and treatment outcome in recent-onset rheumatoid arthritis. Egypt Rheumatol Rehabil. 2016; 43 (3): 143–9. DOI: 10.4103/1110-161X.189824
  36. Cypers H., Varkas G., Beeckman S. et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016; 75: 1357–62. DOI: 10.1136/annrheumdis-2015-208025
  37. Knyazev O.V., Kagramanova A.V., Korneeva I.A. et al. The use of fecal calprotectin in monitoring activity of inflammatory bowel diseases. Ther Arkh. 2019; 91 (4): 53–61 (in Russ.). DOI: 10.26442/00403660.2019.04.000229
  38. Lyatifova N.F., Melikovа A.D., Afandiyev A.M. Antimicrobial peptides with different complications of diabetes. Biomedicine (Baku). 2019; 17 (2): 29–32 (in Russ.). DOI: 10.24411/1815-3917-2019-10014
  39. Mikhailichenko M.I., Shapovalov K.G., Mudrov V.A. The effect of calprotectin on intercellular interaction activity in case of local cold injury. Siberian Medical Review. 2020; 2: 74–9 (in Russ.). DOI: 10.20333/2500136-2020-2-74-79
  40. Kabanova A.A. Diagnostics of inflammatory diseases of the maxillofacial region and neck by the level of elastase and myeloperoxidase activity of oral fluid. Meditsinskie novosti. 2019; 11 (302): 62–5 (in Russ.).
  41. Gellhaar S., Sunnemark D., Eriksson H. et al. Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease. Cell Tissue Res. 2017; 369 (3): 445–54. DOI: 10.1007/s00441-017-2626-8